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OBJECTIVE: Previous survey-based research suggested that
hepatitis C patients receive suboptimal care in primary care
settings. The aim of our study was to define the actual level
of care hepatitis C patients receive in primary care clinics.
METHODS: Medical records of 229 hepatitis C antibody-
positive (group 1), 229 hepatitis C antibody-negative (group
2), and 229 patients not tested for hepatitis C antibody
(group 3) were reviewed to assess the indications for hep-
atitis C testing and the subsequent management and referral
of hepatitis C antibody-positive patients diagnosed in pri-
mary care clinics. In addition, the compliance of primary
care physicians with hepatitis C screening and testing guide-
lines was assessed.
RESULTS: Only 16% of group 1 and 10% of group 2 patients
were tested for hepatitis C based on physician-identified risk
factors. Only 1% of group 3 patients had documented dis-
cussion of hepatitis C risk factors during their initial visit
with a primary care physician. The majority of hepatitis C
antibody-positive patients was appropriately evaluated in
primary care clinics, and most (77%) hepatitis C RNA-
positive patients with elevated liver enzymes were referred
for subspecialty care. Of the 59 patients who underwent
liver biopsy, 40% had bridging fibrosis or cirrhosis.
CONCLUSIONS: Hepatitis C testing is rarely initiated in pri-
mary care clinics based on physician-identified risk factors.
Interventions should be developed to optimize early diag-
nosis of hepatitis C as significant liver disease may be
present despite the absence of symptoms. (Am J Gastroen-
terol 2003;98:639–644. © 2003 by Am. Coll. of Gastroen-
terology)
INTRODUCTION
Approximately four million Americans have antibodies to
the hepatitis C virus (anti-HCV), 74% of whom are chron-
ically infected (1). Chronic hepatitis C infection is the most
common cause of end-stage liver disease and is the leading
indication for liver transplantation in the United States (2).
The economic impact of chronic hepatitis C infection in the
United States is projected to exceed $1 billion per year in
direct medical costs between the years 2010 and 2019 (3).
The overall scope of this disease makes it a common and
important challenge to both primary care physicians and
subspecialists.
There are numerous potential benefits to diagnosing hep-
atitis C in the presymptomatic phase. Diagnosis of hepatitis
C provides the patient with the opportunity to be counseled
regarding behaviors that may transmit the infection to oth-
ers. Diagnosis also allows the health care provider to edu-
cate the patient regarding behaviors that may hasten the
progression of liver disease (such as alcohol intake), and
provide the patient with appropriate preventive services
(hepatitis A vaccination) (4, 5). Finally, diagnosis allows the
patient to be evaluated for hepatitis C therapy. Over the last
decade, the efficacy of hepatitis C therapy has improved
significantly. Hepatitis C therapy leads to sustained clear-
ance of the virus in approximately 50% of all patients who
are treated and may slow or prevent the progression of
hepatitis C-related liver disease (6–9). Given the benefits of
early diagnosis, it is important to ensure that health care
providers are equipped to identify individuals who are at
risk for hepatitis C and to provide adequate care for those
who test positive.
Previous surveys of primary care physicians demon-
strated a number of potential knowledge deficits that may
impact both the diagnosis and subsequent care of patients
with hepatitis C. Despite recommendations to ask all pa-
tients about hepatitis C risk factors (5), only 59% of primary
care physicians reported doing so routinely (10, 11). In
addition, only 68% of primary care physicians reported
routinely testing outpatients with elevated liver enzyme
levels for hepatitis C (12). In these same studies, approxi-
mately one-third of primary care physicians reported they
do not routinely refer anti-HCV-positive patients with ele-
vated liver enzyme levels to a subspecialist. These findings
suggest that a significant proportion of patients with hepa-
titis C may remain undiagnosed despite receiving routine
health care. Because less than 1% of primary care physi-
cians reported prescribing hepatitis C therapy (10), the vast
majority of hepatitis C patients who are not referred will not
have access to therapy. If self-reported practice mirrors
reality, hepatitis C patients may receive suboptimal care. To
date, there has been no report on the actual care hepatitis C
patients received in primary care clinics.
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The primary aims of this study were to determine: 1) the
indications for hepatitis C testing in primary care clinics, 2)
the subsequent management and referral of hepatitis C an-
tibody-positive patients diagnosed in primary care clinics,
and 3) primary care physicians’ compliance with guidelines
for hepatitis C screening and testing. In addition, we de-
scribe the extent of hepatitis C-related liver disease in the
cohort of patients who underwent further evaluation.
MATERIALS AND METHODS
Setting
This study was undertaken after approval by the University
of Michigan Institutional Review Board. The University of
Michigan primary care system (family medicine, general
internal medicine, pediatrics, and combined medicine/pedi-
atric clinics) includes 26 community-based primary care
clinics and seven primary care clinics located on the Uni-
versity Hospital campus. Annually, the primary care system
handles approximately 900,000 outpatient visits.
Subjects
The University of Michigan’s clinical laboratory database
was used to identify all patients above the age of 18 yr seen
in a primary care clinic, who tested positive for hepatitis C
antibody (anti-HCV) using enzyme immunoassay (EIA) be-
tween January 1, 1998, and December 31, 1999 (group 1).
Two control groups were studied. The first control group
included patients who tested negative for anti-HCV during
the same period, matched for age, sex, and clinic site (group
2). The second control group were patients matched for age,
sex, and clinic site, who were not tested for hepatitis C
(group 3).
Data Collection
Each patient’s electronic notes, on-site clinic charts, labo-
ratory results, and records of clinic attendance were re-
viewed. Information on sociodemographics, indication for
hepatitis C testing, laboratory use of hepatitis C-related
tests, documentation of referral, and inquiry into hepatitis C
risk factors was entered on a data abstract form.
Three physicians participated in the chart review and data
abstraction process. To standardize data abstraction, the first
50 charts were reviewed individually by all three physicians.
The data forms were compared, and differences were found
in four (8%) forms. In all but one case, the difference
involved a single data field. These differences were resolved
through a joint discussion among the three reviewers. Of the
remaining charts, 28% were reviewed by at least two re-
viewers, and the rate of discordance was less than 1%.
Indication for Hepatitis C Testing
Indication for hepatitis C testing for group 1 and 2 patients
was based on explicit documentation of the actual reason(s)
the primary care physicians ordered hepatitis C testing on
the date the tests were performed.
Laboratory Testing
To determine if additional HCV testing was ordered by
primary care physicians, computerized laboratory results on
all HCV tests up to 1 yr from the date of initial positive
anti-HCV testing by EIA were searched. To differentiate
between further testing ordered by primary care physicians
versus reflex confirmatory tests initiated by the hospital
laboratory, only tests ordered after the anti-HCV (EIA)
result had been reported were included.
To determine if abnormal liver enzyme levels triggered
hepatitis C testing and if patients who tested positive for
anti-HCV were evaluated for liver disease, computerized
laboratory results on liver biochemistries for the period 1 yr
before and 1 yr after the initial anti-HCV test of group 1
patients were searched.
Referral
Referral for subspecialty care was determined by reviewing
primary care physicians’ notes for documentation of referral
and searching the health system appointment database for
any scheduled gastroenterology/liver clinic appointments
within 1 yr of the initial anti-HCV testing. A patient was
considered to be “referred” if the primary care physician
described a referral plan or an appointment in the gastroen-
terology/liver clinic was made, regardless of actual atten-
dance in the subspecialty clinic. Within our health system,
approximately 95% of subspecialty care of hepatitis C pa-
tients are provided by hepatologists, and the remaining 5%
by gastroenterologists and infectious disease specialists.
Extent of Liver Disease
Biochemical, virological, and histological data were col-
lected on all patients who were seen in gastroenterology/
hepatology clinics. Histological data were obtained by re-
viewing pathology reports. All liver biopsies were read by
one of two pathologists.
Compliance With Screening Recommendations
The majority of the anti-HCV testing was not performed
during the patients’ first visit to the health system. To
determine if there was any delay in identification of patients
who were at risk of hepatitis C, medical records of the initial
visit were reviewed for documentation of inquiry into hep-
atitis C risk factors. The risk factors searched for included:
injection drug use (IDU), blood transfusion before 1992, use
of intranasal cocaine, multiple sexual partners, occupational
exposure to blood or contaminated needles or instruments,
history of sexually transmitted disease, birth to mother with
hepatitis C, and history of acute hepatitis. The first visit was
identified through the health system database. Given the
relatively recent discovery of hepatitis C, only first visits
that occurred after January 1, 1993, were reviewed.
Data Analyses
All data were entered into a Microsoft Excel spreadsheet
and analyzed using the SPSS 9.0 (SPSS, Chicago, IL) sta-
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tistics package. Comparisons between groups 1, 2, and 3
were made using simple t test.
RESULTS
During the study period, 16,383 anti-HCV (EIA) tests were
performed on 13,669 patients in our clinical laboratory. Of
these, 7,450 tests were ordered in primary care clinics on
patients 18 yr old. Thus, anti-HCV (EIA) test was ordered
for approximately 0.8% of primary care visits.
Demographics
The demographics of groups 1, 2, and 3 were similar (Table
1).
Indications for Hepatitis C Testing
The indications for hepatitis C testing are shown in Table 2.
Nearly all patients in both group 1 (217, 95%) and group 2
(219, 96%) had a documented indication for hepatitis C
testing.
Approximately 20% (44 of 229) of patients in group 1 had
more than one indication for hepatitis C testing. The single
most common indication for hepatitis C testing in group 1
patients was a prior diagnosis of hepatitis C. Most of the
patients who had a previous diagnosis of hepatitis C were
diagnosed at the time of blood donation. None of the pa-
tients who had a previous diagnosis of hepatitis C had
undergone evaluation or treatment for hepatitis C.
When the patients with a previous diagnosis of hepatitis
C were excluded, the most common indications for hepatitis
C testing were abnormal liver enzymes (26%), history of or
risk factor for hepatitis B (14%), patient request (11%), and
history of IDU (11%). Our clinical laboratory provides a
“hepatitis screening panel,” which includes tests for hepa-
titis A, B, and C. Physicians who choose the “hepatitis
screening panel” for evaluation of hepatitis B also receive
hepatitis C test results.
Among the patients in group 2, the most common indi-
cations for hepatitis C testing were abnormal liver enzymes
(31%) and history of or risk factor for hepatitis B (34%).
Very few patients in either group were tested because of
physician-identified risk factors for hepatitis C: 16% in
group 1 and 10% in group 2.
Laboratory Evaluation of Group 1 Patients
Our health system laboratory automatically confirms posi-
tive anti-HCV (EIA) test results. During the first 8 months
of the 24-month study period, recombinant immunoblot
assay was performed, whereas in the subsequent 16 months,
qualitative polymerase chain reaction (PCR) assay for hepatitis
C virus RNA was performed. Of the 229 anti-HCV-positive
patients, 97 had reflex recombinant immunoblot assay,
whereas 132 had reflex PCR assay. Hepatitis C genotyping
was ordered in three (1.2%) anti-HCV-positive patients.
Repeat testing for anti-HCV by EIA was requested on 12
(5%) patients, all of whom had negative recombinant im-
munoblot assay or PCR result during reflex testing initiated
by the hospital laboratory.
The majority (150 of 229, 66%) of the patients were
tested for ALT on or before the day of the anti-HCV testing.
Of the 79 patients who had not been tested, 52 (66%) had
ALT testing ordered by the primary care physician during
the year after the anti-HCV test, 39 of whom had detectable
HCV RNA. For the remaining 27 anti-HCV-positive pa-
tients who did not have liver biochemistries tested, 15 were
PCR positive and 13 were referred. Forty-four patients had
Table 1. Demographics of Patients Undergoing Anti-HCV (EIA)
Testing in Primary Care Clinics







Total 229 229 229
Gender
Male 128 (56) 128 (56) 128 (56)
Female 101 (44) 101 (44) 101 (44)
Race
White 176 (77) 175 (76) 172 (75)
Black 21 (9) 23 (10) 22 (10)
Asian 9 (4) 12 (5) 7 (3)
Hispanic 3 (1) 1 (1) 4 (2)
Unknown 20 (9) 18 (8) 24 (10)
Age (yr)
Mean  SD 44.1  8.7 42.9  9.0 43.7  8.4
Range 22 – 77 21 – 78 19 – 74
Ordering clinic
Internal medicine 152 (67) 150 (66) 154 (67)
Family medicine 75 (32) 76 (33) 71 (31)
Medicine/pediatrics 2 (1) 3 (1) 4 (2)
Table 2. Indications for Anti-HCV (EIA) Testing in Primary Care
Patients (Expressed as Percentage)






Transfusion before 1992 3 5
STD or multiple sexual partners* 3 3
Cocaine use 2 1
Any of the above 16 10
Liver disease
Abnormal liver enzymes 26 31
History of acute hepatitis or
abnormal liver enzymes
8 6
Signs or symptoms attributed to
liver disease
3 4
Any of the above 35 40
Other
Previous diagnosis of hepatitis C 26 0
Patient requested hepatitis C
testing
11 17
History of or risk factors for
hepatitis B
14 34
STD  sexually transmitted diseases.
* More than 20 lifetime partners.
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detectable HCV RNA and normal ALT level, nine had
normal ALT on repeat testing during the subsequent year
and were not referred, 14 were referred for subspecialist
care, and the other 21 (48%) patients had no further testing
or referral.
Referral of Group 1 Patients
Overall, 139 (59%) anti-HCV-positive patients were re-
ferred for further evaluation of hepatitis C. They included
77% of the patients who were HCV RNA positive with
elevated ALT and 39% of patients who were HCV RNA
positive with normal ALT (Fig. 1).
Of the 20 patients who were HCV RNA positive with
elevated ALT who were not referred for subspecialist care,
a reason for not referring was documented in 14 patients:
low efficacy/significant side effects of therapy (7), signifi-
cant psychiatric comorbidity (4), and absence of symptoms
related to hepatitis (3).
Liver Disease in Group 1 Patients
One hundred thirty nine (61%) group 1 patients underwent
further evaluation in the gastroenterology/hepatology clin-
ics. The majority of the patients seen in subspecialty clinic
had elevated ALT levels (78%) and were viremic (87%)
(Table 3). Of the 30 patients with normal liver enzymes, 26
(87%) had normal values on at least two occasions. Of the
18 patients who had undetectable hepatitis C RNA, 10 were
retested and all remained PCR negative.
Fifty-seven patients underwent liver biopsies. All had
detectable HCV RNA, 51 (90%) had elevated ALT levels.
Only 9% of these patients had no fibrosis, whereas 40% had
bridging fibrosis or cirrhosis (Table 3).
Compliance With Hepatitis C Screening
Recommendations
The majority of patients in all three groups had an initial
visit after January 1, 1993: 93%, 91%, and 88% in groups 1,
2, and 3, respectively. Less than 10% of patients in each
group had documentation of being asked about both IDU
and history of a blood transfusion before 1992—the two
most common risk factors for hepatitis C, during their initial
visit (Table 4). Hepatitis C antibody testing was performed
during the initial visit in 66 (29%) group 1 and in 11 (5%)
group 2 patients. The vast majority (94%) of group 1 pa-
tients tested during the initial visit had a known diagnosis of
hepatitis C.
During the initial visit, 66 (29%) group 1 patients were
asked about a history of IDU and 37 responded positive, 18
(8%) were asked about a blood transfusion before 1992 with
nine reporting yes. All the patients with an affirmative
response to either of the above questions had a known
diagnosis of hepatitis C. When the patients with a previous
diagnosis of hepatitis C were excluded, only 29 (13%)
Figure 1. Referral of hepatitis C antibody-positive (EIA) primary care patients to gastroenterology/hepatology clinic (n  229 patients).
N/A  not available.
Table 3. Clinical Features of the 139 Hepatitis C Antibody (EIA)-
Positive Patients Referred to Gastroenterology/Hepatology Clinics




1–2  ULN 29 (27)
2–5  ULN 69 (63)
5  ULN 11 (10)
HCV RNA
PCR positive 121 (87)
PCR negative 18 (13)
Histology (57 patients)*
No fibrosis 9 (16)
Minimal/portal fibrosis 21 (37)
Septal fibrosis 4 (7)
Bridging fibrosis 8 (14)
Cirrhosis 15 (26)
ULN  upper limit of normal.
* None of the patients had clinical or biochemical evidence of hepatic decompen-
sation. All were viremic (HCV PCR positive), and 90% had elevated ALT.
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patients were asked about IDU, and none was asked about
blood transfusion before 1992.
The charts of the index visit of group 3 patients were
reviewed to assess the frequency in which hepatitis C risk
factors were discussed during a routine office visit. Only
two of 221 (0.9%) patients had documented discussion of
IDU or blood transfusion history.
DISCUSSION
Hepatitis C is a major health problem in the United States
with significant medical, economic, and social conse-
quences. Given the impact of this disease, the role of pri-
mary care physicians as gate-keepers in the U.S. health care
system, and concerns about suboptimal care raised in pre-
vious surveys, this study was undertaken to determine the
actual care hepatitis C patients receive in primary care
clinics.
The initial visit to a primary care clinic is generally
considered to be the most thorough visit. During this visit,
the physician obtains a detailed history of current and past
medical history as well as family and social history that may
predispose the patient to certain medical illness(es). In this
study, we found that less than 10% of patients attending a
primary care clinic were asked about the two most common
risk factors for hepatitis C during their initial visit, and less
than 15% of anti-HCV test was ordered because of physi-
cian-identified risk factors. Our findings suggest that hepa-
titis C may be grossly underdiagnosed in primary care
clinics. Failure to recognize and test patients who are at risk
may lead to delays in diagnosis and treatment.
We acknowledge that our study was based on retrospec-
tive chart review of documented risk factor inquiry. It is
possible that inquiries were made but not recorded. It is also
possible that primary care physicians are overwhelmed by
the long list of diseases (HIV infection, sexually transmitted
disease, cancers, coronary artery disease, etc) for which risk
factors should be inquired; therefore, omissions are inevi-
table. Because of time constraints in busy clinics, inclusion
of risk factors for hepatitis C in a standardized intake ques-
tionnaire may improve the rate of identification of hepatitis
C patients in primary care clinics. Self-administered ques-
tionnaires are also less confrontational and may yield more
reliable answers on sensitive issues such as history of IDU.
In this study, we found that none of the 29 group 1 patients
who were not known to have hepatitis C responded yes
when asked about history of IDU during their initial visit.
Although some of these patients may have acquired hepa-
titis C through other routes, it is possible that answers to
casual direct inquiry may be inaccurate. A review of the
intake questionnaires used in our health care system dem-
onstrated that only one of seven that are currently used
included questions on risk factors for hepatitis C. Our results
show that if the diagnosis of hepatitis C is to be based on
testing at-risk individuals, this expectation is currently not
met.
The majority of anti-HCV-positive patients had been
tested for ALT level before or on the day of hepatitis C
testing. Of the remaining patients, one-third did not have
ALT testing up to 1 yr after they were known to be anti-
HCV positive. Because of the correlation between abnormal
ALT and referral to a subspecialist, and the potential impact
of ALT level on decisions regarding liver biopsy and treat-
ment, initial evaluation of liver disease such as assessing
liver biochemistry should be initiated in the primary care
clinic. Half of the patients with detectable HCV RNA and
normal ALT had no further ALT testing or referral. The
1997 National Institutes of Health Consensus Statement on
Hepatitis C did not recommend liver biopsy or treatment for
hepatitis C patients with normal ALT level except in the
context of clinical trials (2). However, hepatitis C patients
may have fluctuating ALT levels, and 30% of hepatitis C
patients with persistently normal ALT levels have histolog-
ical evidence of liver disease (13). In light of the significant
improvement in efficacy of hepatitis C treatment in recent
years, we recommend that referral for further evaluation be
considered for all patients who are HCV RNA positive
regardless of their ALT levels.
Although the main focus of this research was to determine
the actual level of care hepatitis C patients receive in pri-
mary care clinics, we were also able to gather significant
information on the spectrum of liver disease in these pa-
tients. The majority of anti-HCV-positive patients was vire-
mic and had elevated ALT levels. Despite the absence of
symptoms, 40% of the patients who underwent liver biopsy
had bridging fibrosis or cirrhosis. We acknowledge that only
Table 4. Primary Care Physicians’ Compliance With Hepatitis C Risk Factor Screening Recommendations During the Initial Visit*







Total 214 209 201
Patient was asked about:
IDU 66 (31) 36 (17) 53 (26)
Transfusion before 1992 18 (8) 5 (2) 7 (3)
IDU as well as transfusion before 1992 21 (10) 15 (7) 14 (7)
Cocaine use 4 (2) 7 (3) 11 (5)
History of acute hepatitis 12 (6) 4 (2) 2 (1)
* Patients with initial visit before January 1, 1993, were excluded.
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a minority of the patients in this study underwent liver
biopsy, and there is a possibility of selection bias. However,
it is worth noting that even if we use the entire cohort of
anti-HCV-positive patients as denominator, our results still
show that at least 10% (23 of 229) of anti-HCV-positive
patients presenting to a primary care clinic had advanced
liver disease at the time of diagnosis.
In summary, we found that hepatitis C testing in primary
care clinics is seldom initiated because of physician-identi-
fied risk factors. Our study also showed that less than 10%
patients were asked about hepatitis C risk factors during the
initial visit to their primary care physicians. We recognize
that there are limitations in our study, and our observations
may not be generalizable to other health care systems in this
country or in other countries. Nevertheless, our findings
suggest that more effective mechanisms must be developed
to identify individuals who are at risk for hepatitis C to
ensure early diagnosis and intervention. Early diagnosis is
important as our data suggest that at least 10% of patients
had advanced liver disease despite the absence of symp-
toms. Once the diagnosis of hepatitis C was made, most
patients in this study had appropriate initial evaluation and
referral. Simple algorithms designed for primary care phy-
sicians with regular updates may further improve counsel-
ing, initial evaluation, and referral such that care of hepatitis
C patients may be optimized without overburdening health
care resources.
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